Clomipramine updated on 10-20-2025

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
All congenital malformations (majors, minors, majors and minors, or unspecified)1.20 [0.94, 1.53]0%2 studies30,6301,400not evaluable ROB-
Major congenital malformations1.20 [0.94, 1.53]0%2 studies30,6301,400not evaluable ROB-
Cardiac septal defects1.85 [1.24, 2.77]-1 study1,399not evaluable ROB3.10 [1.77; .]
Congenital heart defects1.49 [1.03, 2.15]-1 study1,399not evaluable ROB2.34 [1.21; .]

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
Early intrauterine deaths (< 22 weeks) / Spontaneous abortions1.85 [0.87, 3.94]0%3 studies2514not evaluable ROB-
Elective/induced termination of pregnancy17.97 [0.34, 938.20]-1 study141not evaluable ROB-

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROBE-value
ASD (Autism spectrum disorder): Diagnosis1.76 [1.01, 3.06]-1 study369235not evaluable ROB2.92 [1.13; .]
ASD (Autism spectrum disorder): Diagnosis/Risk1.76 [1.01, 3.06]-1 study369235not evaluable ROB2.92 [1.13; .]

Hide endpoints reported in only one study ...